ABSTRACT: It has previously been reported that sputum induction is successful and safe in the clinical research setting. The authors examined the success and safety of sputum induction in routine clinical practice in patients with asthma or chronic airflow limitation of varying severity.
Induced sputum examination has been increasingly used in the research of asthma and other airway conditions. Results have shown that sputum cell counts have a place in clinical practice [1±6] but, because an inhaled aerosol of hypertonic saline is a bronchoconstrictor stimulus [7, 8] , there have been concerns about the safety of sputum induction, particularly in patients with uncontrolled asthma or chronic airflow limitation. Safety has been addressed in three recent publications of research subjects with asthma, most of whom had a baseline forced expiratory volume in one second (FEV1) >60% [9±11]. In the present study, the success and safety of sputum induction in clinical practice in patients with asthma of varying severity and in patients with smoking related chronic airflow limitation was investigated. Additional safety precautions were taken and a large number of patients with an FEV1 <60% were included.
Methods

Design
This was a retrospective analysis of 329 consecutive sputum inductions, performed as part of the clinical evaluation of patients with asthma or chronic airflow limitation who were attending the Firestone Regional Chest and Allergy Clinic between September 1, 1997 and March 31, 1998.
Patients
The patients with asthma had episodic symptoms of chest tightness, wheezing or dyspnoea plus a provocative concentration causing a 20% fall in FEV1 by methacholine (PC20) <8 mg . mL -1 (if the FEV1 was $70 % predicted (pred)) or an improvement in FEV1 of >12% after 200 mg of inhaled salbutamol (if the FEV1 was <70% pred) (table 1). The FEV1 after salbutamol was moderately reduced (40±59% pred) in 69 (23%) patients and severely reduced (<40%) in 24 (8%) patients. The severity of asthma, according to the level of treatment, was moderate in 48% and severe in 40% [12] . The patients with chronic airflow limitation had an onset of respiratory symptoms >40 yrs of age, >15 pack year smoking history, an FEV1 <70% pred and an improvement in FEV1 <10% after inhaled salbutamol. The FEV1 after salbutamol was moderately reduced in 8 (32%) patients and severely reduced in 11 (44%) patients.
Procedures
Clinical details, including sputum induction details, were collected from patient charts using standard patient record forms. In all cases, sputum induction was performed by trained technologists using the method described by PIN et al. [13] , with modifications to improve safety [3] . Aerosols of hypertonic saline at 3%, 4%, and 5% were each inhaled for 7 min via a Medix ultrasonic nebulizer (Clement Clarke International Ltd., Harlow Essex, UK) which has an output of 0.87 mL . min -1 and an aerosol mass median diameter of 5.58 mm. Patients were asked to cough into a container after each period. The standard safety precautions were to premedicate with 200 mg of inhaled salbutamol, then to measure the FEV1 at baseline and after each period of saline induction, not to increase the dose of saline if there was a fall in FEV1 of 10±19%, and to discontinue saline inductions if the FEV1 fell $20%. In the case of an excessive fall in FEV1 ($20%) further salbutamol was administered and the patient was kept in the laboratory until the FEV1 had returned to within 5% of baseline. If the baseline FEV1 was <70% pred, further safety precautions were taken by starting the inductions with normal saline and using shorter times of inhalation, e.g. 30 s followed by 1, 2 and 4 min [3] . Other indices for caution were a previous fall in FEV1 $20% during sputum induction, the presence of significant airway reversibility ($12%), or the presence of a clinical exacerbation. Where there was concern about safety, the inhalations were discontinued when the expectorate was considered to contain enough sputum (>70 mg) for examination. Sputum was selected from the expectorate and processed within 2 h as described by PIZZICHINI et al. [14] . Successful inductions was defined as those in which nonsquamous total and differential cell counts were obtained which contained macrophages. Squamous cell contamination was <20% and cell viability was >40%.
Data analysis
Descriptive statistics were used to summarize the baseline characteristics of the patients and the results were expressed as meanstandard deviation (SD). Success, medication use, final saline concentration administered, the incidence of excessive falls in FEV1 per group and other noncontinuous data were expressed as counts or percentages. Pearson's correlation coefficient was used to evaluate the change between the pre-induction post salbutamol FEV1 and the value after the last concentration of saline. Multiple linear regression was used to identify potential risk factors to predict a fall in FEV1 during sputum induction. Significance was accepted at the 95% level.
Results
Sputum induction was successful in 93% of all patients regardless of the diagnosis, degree of airflow limitation or the concentration of saline inhaled. Amongst those with asthma, the highest concentration of saline inhaled was 0.9% in 17%, 3% in 26%, 4% in 29% and 5% in 28% of patients; amongst those patients with chronic airflow limitation, it was 0.9% in 56%, 3% in 24%, 4% in 4% and 5% in 16%. Excessive bronchoconstriction, defined as a fall in FEV1 of $20%, only occurred in 23 (8%) of all patients ( fig. 1 ). Seven of these 23 patients were on long acting b 2 -agonists as part of their maintenance treatment but, in a regression model, neither this or methacholine PC20 could be identified as risk factors for a fall in FEV1.
Of 77 patients with an FEV1 between 40±59%, 8% fell by $20% and of 35 patients with an FEV1 <40%, 6% fell by $20%. There was no correlation between the maximal fall in FEV1 and baseline (postbronchodilator) FEV1 % pred (r=0.12). No subject developed refractory bronchoconstriction or required emergency treatment.
Discussion
This is the first formal investigation of the success and safety of the method of sputum induction described by PIN et al. [13] and modified by PIZZICHINI et al. [14] in clinical practice. Sputum induction performed carefully by trained staff in routine clinical practice was successful in 93% of patients with asthma or chronic airflow limitation, in spite of most (n=239) patients not receiving the maximum saline concentration and many (n=66) only receiving isotonic saline. Excessive bronchoconstriction only occurred in 8% of patients with asthma and was not predicted from the baseline postbronchodilator FEV1. All 23 patients who had a fall in FEV1 >20% following sputum induction were treated with additional inhaled salbutamol (200±400 mg), and in all cases their FEV1 returned to within 5% of the baseline (postbronchodilator) value within 30 min. The results indicate that sputum induction can be carried out safely and successfully in clinical practice, even in the presence of moderate or severe airflow limitation.
The safety results were slightly better than those reported by WONG et al. [9] , similar to those of HUNTER et al. [11] and slightly worse than those reported by DE LA FUENTE et al. [10] , while the success was similar to that reported in the three studies described above. This is not surprising, when a comparison is made between the subjects studied and the procedures used in the three studies. WONG et al. [9] studied patients with asthma with a postbronchodilator FEV1 >60% and all their patients inhaled an aerosol of 3% hypertonic saline for 20 min before repeating the FEV1. As a result, earlier falls in FEV1 were not detected and a higher occurrence of excessive falls were observed. This may be the reason that they were able to illustrate that the saline-induced falls in FEV1 were greater when the baseline FEV1 was lower, a relationship not observed in other studies, including the present one. DE LA FUENTE et al. [10] studied a more severe group of asthmatic subjects with an FEV1 >1 L. They used the method of induction described by PIN et al. [13] , giving 3% saline, followed by 4% and then 5%, for 5 min with each saline concentration given twice. However, they did not proceed to the next concentration if the FEV1 fell by 10% and they discontinued the inhalations if adverse symptoms developed. HUNTER et al. [11] studied a mild group of asthmatic subjects with a mean FEV1 of 83%, their induction procedure was similar to DE LA FUENTE et al. [10] except each concentration was only given once. In the present study, a similar range of asthma severity as used by DE LA FUENTE et al. [10] , was examined however, it also included a large number of patients with moderate to severe airflow limitation. During these inductions additional safety precautions were taken; if the baseline postbronchodilator FEV1 was <70%, or if there were suggestions of more severe airway hyperresponsiveness, the inhalations with normal saline were initiated for shorter periods of time. The inductions were also discontinued when an apparently adequate macroscopic sputum sample was produced.
The results of the present study, specifically illustrate the safety of the method of sputum induction used. Many of the patients had severe asthma; 112 inductions were carried out on patients with a prebronchodilator FEV1 <60%, and 40 inductions were performed on patients with a prebronchodilator FEV1 <1L. In spite of this, only 8% of patients had excessive bronchoconstriction (fall in FEV1 $20%), and none of these were in the group with moderate to severe airflow limitation. Only two patients, both of whom had asthma, had a fall in FEV1 >30%. One had a baseline FEV1 of 103% pred, and the induction consisted of 3% for 2 runs and 4% for one run; there was a 10% fall in FEV1 following the first run which did not worsen after the second run but fell to 32% after the third run. The other patient had a baseline FEV1 of 75% pred and received 3%, 4% and 5% saline; the FEV1 fell by 9% after 4% saline, and by 50% after 5% saline. The airway constriction was quickly reversed by inhaled salbutamol in both cases. These infrequent episodes of more severe induced airway constriction highlight the importance of being cautious, having resuscitation equipment available in the laboratory, and for having a responsible physician in the building when the inductions are performed. To conclude, the method of sputum induction used in this report can be successfully and safely performed by trained staff in clinical practice, even in patients with moderate or severe asthma or chronic airflow limitation. 
